Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 27Breast Neoplasms 23Neoplasm Metastasis 14Glioma 14Carcinoma, Non-Small-Cell Lung 14Lymphoma 12Lung Neoplasms 11Glioblastoma 11Neuroblastoma 10Lymphoma, Non-Hodgkin 9Carcinoma, Renal Cell 9Brain Neoplasms 9Medulloblastoma 8Ovarian Neoplasms 7Neoplasms 7Multiple Myeloma 7Ependymoma 7Carcinoma, Hepatocellular 7Wilms Tumor 6Thyroid Neoplasms 6Sarcoma 6Rectal Neoplasms 6Pancreatic Neoplasms 6Osteosarcoma 6Melanoma 6Fallopian Tube Neoplasms 6Central Nervous System Neoplasms 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5

Interventions

Fluorouracil 3Radiotherapy 2Cisplatin 2Cetuximab 2rocakinogene sifuplasmid 1durvalumab 1VGX-3100 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Mitomycin 1Magnetic Resonance Spectroscopy 1MEDI0457 1Ipilimumab 1Immunoglobulin G 1Disulfides 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anal Canal Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡